Searched for: in-biosketch:true
person:loftoh01
The effects of commuting on obesity [Meeting Abstract]
Creange, C; Hold, R; Hyde, D; Fazzolari, S; Kaufman, L; Lofton, H
Aims: Physical inactivity is proven to be correlated with obesity. Our study aim was to evaluate the relationship between commuting mode/duration and % body weight lost (%BWL) before and after weight loss intervention. Our hypothesis was that longer and inactive commuting would correlate with both a higher baseline body mass index (BMI) and lower %BWL. Methods: We collected patient commuting data from October 2015 to March 2016. Data included BMI and %BWL at one, two and three months after intervention, as well as commuting length, type of commute, and number of days at work. Weight loss intervention included dietary and exercise management, as well as pharmacotherapy. Patients were stratified into commuting and non-commuting groups. The primary outcome was %BWL after intervention, correlated to commute, commuting length, and type of commute. Results: There were 318 patients in the commuting group and 51 non-commuters. Initial BMI for the two groups was similar (37.1 vs 36.3, p=.514). Commuters were significantly younger (44 vs 62.2 years, po.0001) and had lower use of hypertensive medications (21% vs 45%, po.0001). There was no difference seen in %BWL between the two groups after one month of therapy (3.1% vs 3.0%, p=.783), two months (5.1% vs 4.9%, p=.831), or three months (6.9% vs 7.2%, p=.806). Duration of commute was also not correlated with %BWL (p=.383 at three months). Male gender, walk/biking commute mode, and hypertension medications were independently predictive of greater %BWL. Males had an average of 0.9% greater %BWL (p=0.030), subjects that used a bike or walked as their commute mode had an average of 1.7% greater %BWL (p=0.0091), and those with hypertension medications had an average of 1.0% greater %BWL (p=0.015). Conclusion: Commuting time and duration do not appear to have an effect on patient obesity. However, those with an active mode of commute were able to show greater weight loss after intervention
EMBASE:619778135
ISSN: 1878-7533
CID: 2886382
The efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: Subgroup analysis across SCALE and phase 2 randomized trials
Ard, J; Cannon, A; Lewis, C E; Lofton, H; Vang Skjoth, T; Stevenin, B; Pi-Sunyer, X
The efficacy and safety of liraglutide 3.0 mg vs. placebo, as adjunct to diet and exercise, was evaluated in racial subgroups. This post hoc analysis of pooled data from five double-blind randomized, placebo-controlled trials was conducted in 5325 adults with BMI >/=27 kg/m2 plus >/=1 comorbidity, or BMI >/=30 kg/m2 . Statistical interaction tests evaluated possible treatment effect differences between racial subgroups: White (4496, 84.4%), Black/African-American (550, 10.3%), Asian (168, 3.2%) and Other (111, 2.1%). Effects of liraglutide 3.0 mg on weight loss, associated metabolic effects and safety profile were generally consistent across racial subgroups. All achieved statistically significant mean weight loss at end-of-treatment with liraglutide 3.0 mg vs. placebo: White 7.7% vs. 2.3%, Black/African-American 6.3% vs. 1.4%, Asian 6.3% vs. 2.5%, Other 7.3% vs. 0.49%. Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction-test p-values >0.05). Adverse events were comparable across racial subgroups.
PMCID:6084344
PMID: 26744025
ISSN: 1463-1326
CID: 1901202
Clinical efficacy of a medically supervised low-calorie diet program versus a conventional carbohydrate-restricted diet
Sethi, Monica; Youn, Heekoung; Ren-Fielding, Christine; Lofton, Holly
ORIGINAL:0010580
ISSN: 2165-7904
CID: 2462882
Ghrelin Resting Energy Expenditure Number (GREEN) Study [Meeting Abstract]
Weinshel, Elizabeth; Chua, Deborah; Fielding, George; Lofton, Holly F; Ren-Fielding, Christine; Schwack, Bradley
ISI:000363715905063
ISSN: 1572-0241
CID: 1854422